Current Performance: SiNtx Technologies (NASDAQ: SINT)
SiNtx Technologies is part of the healthcare sector and is in the medical devices industry. The company CEO is B. Sonny Bal. Amedica Corp is engaged in using its silicon nitride technology platform to develop, manufacture, and commercialize a variety of medical devices.
Previous Intraday Performance:
The SINT shares had a previous change of -0.08% which opened at 0.13 and closed at 0.12. It moved to an intraday high of 0.13 and a low of 0.12.
Over the last five trading days, SINT shares returned -20.01% and in the past 30 trading days it returned -42.90%. Over three months, it changed -49.83%. In one year it has changed -58.66% and within that year its 52 week high was 0.35 and its 52 week low was 0.11. SINT stock is 14.08% above its 52 week low.
Our calculations result in a 200 day moving average of 0.22 and a 50 day moving average of 0.19. Right now, SINT stock is trading -45.18% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $2.6m with 21.8m shares outstanding and a float of 21.1m shares. Trading volume was 6,783,094 shares and has experienced an average volume of 3,899,150 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for SiNtx Technologies was -2.89 which ended on 31st of December 2018.
EPS growth is an important number as it indicates the future prospects of SiNtx Technologies; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -66.40% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 5.50% of institutional ownership.
The beta was calculated to be 2.24.
Based on last reported financials, the company’s return on assets is -174.90%, price-to-sales is 1.17 and price-to-book is 0.39.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result